



North Dakota Medicaid Academic Detailing

Quarter 2 2025

Russell Moore (Medicaid Pharmacy Specialist - Acentra Health)
russell.moore@acentra.com

Agenda

- General Updates
- Coverage/Criteria Updates: Diabetes, Renal HCPCS Drugs, Respiratory Drugs
- Prior Authorization (PA) Updates
- Brand/Generic Requirement Updates
- Other



General Updates

- ND Medicaid PA website: <https://ndmedicaid.acentra.com/>
- Preferred Drug List (PDL) Changes
 - Monitor for PDL changes often throughout the year.
 - Save this URL to see the most current version: <https://ndmedicaid.acentra.com/ndpdl/>
- [Procedure Lookup Tool](#)
 - Now available to identify procedure codes that ND Medicaid covers
- Please see the [academic detailing page](#) for information previously presented
- Medicaid Expansion eligibility can now be viewed in the MMIS portal. Under the Eligibility Confirmation header in the Eligibility Inquiry screen, a red banner will display stating “Eligibility is under ND Medicaid Expansion” if the member has eligibility through Medicaid Expansion. Previously, no eligibility results would display for members eligible under Medicaid Expansion.
 - Please visit [Member Eligibility Instructions](#) for detailed information on how to check member eligibility in the MMIS portal.



Criteria Updates: Diabetes Coverage Updates

Effective March 3, 2025: Insulin lispro pens are preferred.

- Vials require PA to verify member has an insulin pump.
- PA is not required for insulin lispro vials when used with Omnipod. If the member uses an Omnipod insulin pump, electronic lookback will confirm pump use within 90 days prior to the insulin claim date of service.

Effective May 1, 2025: Dexcom does not require PA for members using insulin.

- Electronic lookback will confirm insulin use within 90 days prior to the Dexcom sensor claim date of service.
- If the electronic lookback does not confirm insulin use, you can submit a PA request.
- Please see PA details at <https://ndmedicaid.acentra.com/ndpdl/>

Effective July 1, 2025: Januvia, Janumet, Janumet XR, and Jentadueto XR will require PA.

- Tradjenta and Jentadueto will be the only DPP-4 inhibitors that do not require PA.
- Please start transitioning your patients now to avoid treatment disruption.



Criteria Updates: Respiratory Drug Coverage Updates

Effective October 1, 2025: Advair Diskus, Advair HFA, and Airduo Respclick will require PA.

- Dulera will be the only inhaled corticosteroid/long-acting beta agonist (ICS/LABA) inhaler that does not require PA.
 - Dulera contains formoterol and can be used for single-inhaler maintenance-and-reliever therapy (SMART) as recommended in the asthma guidelines.
 - ND Medicaid allows up to two Dulera inhalers per 30-day supply for SMART use.
- Please start transitioning your patients now to avoid treatment disruption.

Criteria Updates: Renal HCPCS Drug Coverage Updates

Effective April 1, 2025: Drugs billed with HCPCS codes that are specific for end stage renal disease (ESRD) in the description require PA.

- PA is required to rule out Medicare eligibility if a member is on renal dialysis or has an ESRD diagnosis.
- Please use the [Procedure Code Look-up Tool](#) to search for the HCPCS codes that require PA.
- Please see prior authorization details at <https://ndmedicaid.acentra.com/ndpdl/>

Prior Authorization Updates

**All of the below medications are new to the market except for generic Cambia.

Drug	PA Status	Class
Cortrophin	PA	>3000 criteria
diclofenac powder pack (generic Cambia)	PA	Migraine
Gomekli	PA	>3000 criteria
Hemiclor	PA	Antihypertensive
Inzirqo	PA	Diuretics
Onapgo	PA	Parkinson's Disease
Otulfi	PA	Cytokine Modulators
Qfitlia	PA	Hemophilia
Raldesy	PA	Non-Solid Dosage Forms
Symbravo	PA	Migraine treatment
Tezruly	PA	Benign Prostatic Hyperplasia
Vanrafia	PA	Chronic Kidney Disease
Xdemvy	PA	Ophthalmic Anti-infectives
Zunveyl	PA	Alzheimer's Disease



Brand Name Requirement Updates

- Brand required by ND Medicaid
 - Prescribers should not submit a DAW request based on ND Medicaid brand preference. Pharmacies can automatically substitute and bill brand name without prescriber intervention when the payer requires brand.
 - Ventolin HFA is the preferred albuterol MDI and does not require PA.
- If a member requires brand name (brand medically necessary), a Dispense as Written (DAW1) PA request must be submitted.
 - DAW criteria must be met, which require a trial of all available generics along with an FDA MedWatch form submitted for each generic trial. The FDA needs to be made aware when a marketed product is not producing expected results.
 - If products have authorized generics, prescriber-requested DAW will not be approved.



Legislative Update

5 or More Psychotropic Drugs

- Previously:

Required PA for members less than 18 years old who are on 5 or more psychotropic drugs for prescribers to have a peer-to-peer consult with a board-certified child and adolescent psychiatrist. Following the consultation, the department approves PA.

- Now:

Department will send letters to prescribers of members who are less than 22 years old who are on 5 or more psychotropic drugs to certify that the medication is medically necessary.

If the prescriber does not certify, the department may deny payment until certification.

Restricted Drug Classes

- Previously:

Department may not prior authorize substantially all drugs in the following restricted classes: antipsychotics, antidepressants, anticonvulsants, antiretrovirals for human immunodeficiency virus, antineoplastics, immunosuppressants for organ transplant

- Now:

Department may prior authorize drugs in the restricted classes if the department will not be able to access supplemental rebate offers due to the existence of the PA exclusion/restriction



Medicaid Newsletters and Emails

- Signing up to receive ND Medicaid provider communications, including updates, news releases, and newsletters is easy.
 - **Step 1:** Go to the [Provider webpage](#).
 - **Step 2:** Click on the Subscribe to News and Alerts button at the bottom of the screen.
 - **Step 3:** Enter your email address and click submit.
 - **Step 4:** Follow directions to set up and choose your subscription options. Select Medicaid Provider Newsletter.

[Accessibility](#) | [Client Rights and Appeals](#) | [Disclaimer](#) | [HIPAA Privacy](#)

| [Nondiscrimination](#) | [Contact](#) | [Privacy Policy](#) | [Security Policy](#)

Subscribe to News and Alerts



Acentra

HEALTH

Accelerating
Better Outcomes